Please assess the completion status of the following clinical trial:

Trial Title: Preventing Osteoporosis Using Denosumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Ambulatory male and female residents with osteoporosis or low bone mass (at risk for fracture) ages 65 and older will be considered if:~* Reside in long-term care institution (nursing home or assisted living facility); and~* HaveOsteoporosis: (1) by bone density \[spine, hip or forearm Bone Mineral Density (BMD) T-score ≤ -2.5\]; (2) A previous adult fragility fracture of the spine or hip; or (3) Would be treated based on FRAX® and the National Osteoporosis Foundation (NOF) treatment thresholds of a 10 year risk of ≥ 20% for a major fracture or ≥ 3% for hip fracture suing femoral neck BMD.~Exclusion Criteria:~* Institutionalized residents with subacute illnesses who are not expected to survive or who will be discharged in \< 2 years.~* Non-ambulatory residents (those who cannot stand and pivot with assistance in order to transfer to the DXA table).~* Those currently on therapy (including bisphosphonate, denosumab, or teriparatide) or who have been on a bisphosphonate for \> 1year during the previous 2 years because some bisphosphonates are long acting.~* Those with a history of hypocalcemia or contraindication for treatment. We will screen for these conditions by detailed history, chart review, and baseline laboratory analyses.~* Those with vitamin D levels \< 25ng/mL will be treated with vitamin D 50,000 IU/wk for 8 weeks; they will be enrolled if the follow-up vitamin D level is 25 ng/mL or more (if after 2 rounds of vitamin D repletion their vitamin D level is not at least 25 ng/mL, they will not be eligible to be randomized into the study).~* Those on dialysis or with stage 5 chronic kidney disease (eGFR\<15ml/min) will be excluded at screening.~* Those requiring tooth extraction or oral surgery will not be enrolled until cleared by a dentist.~* Patients will be allowed to continue on glucocorticoids and anticonvulsants because their use is common in this population.~* Those on glucocorticoids and anticonvulsants will be allowed to continue in the study because their use is common in this population.~* Those on hormone replacement therapy (HRT), raloxifene, or prescribed protective hip pads by their Primary Care Physician (PCP) will be allowed to participate and continue on these therapies.~* We will suggest that participants stop long-term calcitonin as it has been discontinued in Europe due to cancer concerns.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women Denosumab (Type: EXPERIMENTAL): Semi-annual dose for women: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
- Women Placebo Group (Type: PLACEBO_COMPARATOR): Semi-annual for women: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements).
- Men Denosumab (Type: EXPERIMENTAL): Semi-annual dose for men: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
- Men Placebo Group (Type: PLACEBO_COMPARATOR): Semi-annual for men: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements)

Based on this trial design, predict the completion outcome and termination type (if applicable).